Oppenheimer & Co’s Alaunos Therapeutics TCRT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-243
| Closed | -$63K | – | 1427 |
|
|
2022
Q3 | $63K | Sell |
243
-60
| -20% | -$17.4K | ﹤0.01% | 1320 |
|
|
2022
Q2 | $56K | Sell |
303
-170
| -36% | -$16.2K | ﹤0.01% | 1360 |
|
|
2022
Q1 | $47K | Hold |
473
| – | – | ﹤0.01% | 1440 |
|
|
2021
Q4 | $77K | Sell |
473
-382
| -45% | -$83.9K | ﹤0.01% | 1457 |
|
|
2021
Q3 | $233K | Sell |
855
-234
| -21% | -$71.6K | ﹤0.01% | 1326 |
|
|
2021
Q2 | $431K | Buy |
1,089
+530
| +95% | +$247K | 0.01% | 1097 |
|
|
2021
Q1 | $301K | Buy |
559
+366
| +190% | +$228K | 0.01% | 1181 |
|
|
2020
Q4 | $73K | Hold |
193
| – | – | ﹤0.01% | 1319 |
|
|
2020
Q3 | $73K | Hold |
193
| – | – | ﹤0.01% | 1244 |
|
|
2020
Q2 | $96K | Hold |
193
| – | – | ﹤0.01% | 1208 |
|
|
2020
Q1 | $71K | Hold |
193
| – | – | ﹤0.01% | 1140 |
|
|
2019
Q4 | $137K | Hold |
193
| – | – | ﹤0.01% | 1224 |
|
|
2019
Q3 | $125K | Buy |
193
+6
| +3% | +$4.76K | ﹤0.01% | 1203 |
|
|
2019
Q2 | $163K | Sell |
187
-53
| -22% | -$36.4K | ﹤0.01% | 1218 |
|
|
2019
Q1 | $139K | Buy |
240
+7
| +3% | +$2.93K | ﹤0.01% | 1283 |
|
|
2018
Q4 | $65K | Buy |
233
+160
| +219% | +$63.3K | ﹤0.01% | 1202 |
|
|
2018
Q3 | $35K | Hold |
73
| – | – | ﹤0.01% | 1332 |
|
|
2018
Q2 | $33K | Sell |
73
-14
| -16% | -$8.88K | ﹤0.01% | 1312 |
|
|
2018
Q1 | $51K | Sell |
87
-2
| -2% | -$1.25K | ﹤0.01% | 1310 |
|
|
2017
Q4 | $55K | Sell |
89
-4
| -4% | -$2.87K | ﹤0.01% | 1290 |
|
|
2017
Q3 | $86K | Sell |
93
-27
| -23% | -$24K | ﹤0.01% | 1256 |
|
|
2017
Q2 | $112K | Buy |
120
+40
| +50% | +$39.2K | ﹤0.01% | 1255 |
|
|
2017
Q1 | $75K | Sell |
80
-120
| -60% | -$112K | ﹤0.01% | 1256 |
|
|
2016
Q4 | $160K | Buy |
200
+70
| +54% | +$63.1K | ﹤0.01% | 1191 |
|
|
2016
Q3 | $111K | Sell |
130
-4
| -3% | -$3.21K | ﹤0.01% | 1204 |
|
|
2016
Q2 | $110K | Buy |
134
+6
| +5% | +$6.53K | ﹤0.01% | 1160 |
|
|
2016
Q1 | $142K | Sell |
128
-3
| -2% | -$3.07K | ﹤0.01% | 1155 |
|
|
2015
Q4 | $163K | Buy |
131
+7
| +6% | +$11.6K | ﹤0.01% | 1163 |
|
|
2015
Q3 | $167K | Buy |
124
+56
| +82% | +$92.4K | 0.01% | 1204 |
|
|
2015
Q2 | $123K | Buy |
68
+1
| +1% | +$1.55K | ﹤0.01% | 1386 |
|
|
2015
Q1 | $108K | Buy |
+67
| New | +$99.3K | ﹤0.01% | 1402 |
|
|
2013
Q4 | – | Sell |
-67
| Closed | -$39K | – | 1451 |
|
|
2013
Q3 | $39K | Buy |
+67
| New | +$30.2K | ﹤0.01% | 1288 |
|
Other funds holding TCRT
DCM
MP
LCM
AC
SGCA
Oppenheimer & Co's TCRT Position: Q4 2022 in Review
Oppenheimer & Co sold out of Alaunos Therapeutics (TCRT) in Q4 2022, closing a stake of 243 shares — an estimated $63K sold.
Oppenheimer & Co first reported a position in TCRT in Q3 2013 and held it in 32 quarters. The position peaked at $431K in Q2 2021. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.
- Oppenheimer & Co reported no remaining Alaunos Therapeutics position as of Q4 2022 after selling out during the quarter.
- Oppenheimer & Co sold 243 Alaunos Therapeutics shares in Q4 2022, an estimated $63K.
- Oppenheimer & Co first reported a position in Alaunos Therapeutics in Q3 2013 and held it in 32 quarters.
- Oppenheimer & Co's Alaunos Therapeutics position peaked at $431K in Q2 2021.
- 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.
Based on Oppenheimer & Co's 13F filing for Q4 2022, filed 8 Feb 2023.